Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

XSEC:301096 Stock Report

Market Cap: CN¥4.7b

Hangzhou Bio-Sincerity Pharma-TechLtd Past Earnings Performance

Past criteria checks 1/6

Hangzhou Bio-Sincerity Pharma-TechLtd has been growing earnings at an average annual rate of 34.7%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 39.9% per year. Hangzhou Bio-Sincerity Pharma-TechLtd's return on equity is 7.7%, and it has net margins of 20.7%.

Key information

34.7%

Earnings growth rate

28.0%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate39.9%
Return on equity7.7%
Net Margin20.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hangzhou Bio-Sincerity Pharma-TechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:301096 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,025212120321
30 Jun 241,119287172298
31 Mar 241,072287156260
31 Dec 231,017272159240
30 Sep 23900250155203
30 Jun 23786229153184
31 Mar 23673210131164
01 Jan 23607194113163
30 Sep 2257319293149
30 Jun 2247915575120
31 Mar 2242512670110
31 Dec 213741116278
30 Sep 213041015151
30 Jun 21267854844
31 Mar 21211554636
31 Dec 20207575032
31 Dec 19156443515
31 Dec 1882112312
31 Dec 1726-7108
30 Jun 17308110
31 Mar 17275110
31 Dec 16243120
30 Sep 16211120
30 Jun 1616-1110
31 Mar 1616280
01 Jan 1616540
31 Dec 146-240

Quality Earnings: 301096 has a high level of non-cash earnings.

Growing Profit Margin: 301096's current net profit margins (20.7%) are lower than last year (27.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301096's earnings have grown significantly by 34.7% per year over the past 5 years.

Accelerating Growth: 301096's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301096 had negative earnings growth (-15.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).


Return on Equity

High ROE: 301096's Return on Equity (7.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies